ClinicalTrials.gg
RecruitingNCT05797922Updated Apr 4, 2023

To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers

A Phase 1 interventional study of DWP16001 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-04.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by May 2023, 3 years 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effect of food on the pharmacokinetics and safety of DWP16001 after oral administration.

Read the detailed description

The study design is A randomized, Open-label, Oral, Single-dose, Two-way crossover study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A person who has decided to participate voluntarily and agreed in writing prior to the screening procedure after understanding the detailed explanation of this clinical trial.
  2. A person who is 19 years of age or more at the time of screening.
  3. Those with a weight of 50.0 kg or more and a (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less.

Exclusion criteria

Exclusion Criteria:

  1. A person who has a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  2. A person who has a history of gastrointestinal surgery/disease, such as Crohn's disease, ulcer, acute or chronic pancreatitis, which may affect the absorption of drug for clinical trials. (Except for simple appendectomy or hernia surgery)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    DWP16001 to Group A

    Group A: Fasting in Period 1 / Fed in Period 2

    Drug: DWP16001

  • Experimental
    DWP16001 to Group B

    Group B: Fed in Period 1 / Fasting in Period 2

    Drug: DWP16001

Interventions

  • DWP16001 0.3mg

    Also known as: DWP16001 0.3mg

06

What researchers measure

Primary outcomes

  1. AUC0-t of DWP16001

    AUC0-t of DWP16001

    Time frame: 0 to 72 hours

  2. Cmax of DWP16001

    Cmax of DWP16001

    Time frame: 0 to 72 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for May 2023, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 4, 2023
StartActual
Mar 9, 2023
Primary completionEst.
May 31, 2023
CompletionEst.
Nov 30, 2023
Last update
Apr 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05797922
Responsible party
Sponsor
First posted
Apr 4, 2023
Start date
Mar 9, 2023
Primary completion
May 31, 2023 (estimated)
Completion
Nov 30, 2023 (estimated)
Last update
Apr 4, 2023

Study contacts

Daewoong Pharmaceutical
Contact
yoonhye@daewoong.co.kr
080-550-8308
Chungbuk National University Hospital
principal investigator · Chungbuk National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion